Admitted From Home (n = 63) | In Hospital Since Birth (n = 50) | P | |
---|---|---|---|

GA at birth, wk, n (%) | <.001 | ||

Term (≥37) | 54 (86) | 14 (28) | |

Preterm (<37) | 9 (14) | 36 (72) | |

Birth weight (kg), median (IQR) | 3.2 (2.9–3.6) | 1.5 (1.0–3.1) | <.001 |

Sex, n (%) | .71 | ||

Female | 28 (44) | 24 (48) | |

Male | 35 (55) | 26 (52) | |

Congenital anomaly | 7 (11) | 7 (14) | .64 |

Onset, d, n (%) | <.001 | ||

Early (0–6) | 3 (4.8) | 12 (24) | |

Late (7–29) | 32 (51) | 32 (64) | |

Extremely late (30–90) | 28 (44) | 6 (12) | |

Organism | .029 | ||

E coli | 20 (31) | 17 (34) | |

GBS | 23 (36) | 12 (24) | |

L monocytogenes | 3 (4.8) | 0 | |

N meningitidis | 4 (6.3) | 0 | |

H influenzae | 2 (3.1) | 1 (2.0) | |

S pneumoniae | 1 (1.6) | 0 | |

Other | 10 (16)^{a} | 20 (40)^{b} | |

Antimicrobial resistance | |||

AMP^{c} | 15 (24) | 25 (50) | .004 |

AMP+GEN | 2 (3.2)^{d} | 6 (12)^{e} | .069 |

CEF (third) | 6 (9.5)^{f} | 13 (26)^{g} | .020 |

Outcome at last follow-up^{h} | |||

Seizure disorder | 5 (8.5) | 5 (11) | .68 |

Hearing loss | 2 (3.4) | 3 (6.5) | .46 |

Vision problem | 1 (1.7) | 0 | .38 |

Motor problem (spasticity, paresis) | 9 (15) | 10 (22) | .69 |

Developmental delay | 5 (8.5) | 5 (11) | .87 |

Death | 4 (6.3) | 4 (8.0) | .73 |

Duration of antibiotics^{h} | 22 (16–37) | 24 (21–41) | .15 |

Length of hospitalization^{h} | 18 (12–25) | 60 (25–100) | <.001 |

AMP, ampicillin; CEF (third), third-generation cephalosporin; GEN, gentamicin.

↵a Other bacteria from patients admitted from home include the following:

*Klebsiella*spp. (*n*= 3),*Streptococcus bovis*(*n*= 2),*S gallolyticus*(*n*= 1),*E cloacae*(*n*= 1),*C sakazakii*(*n*= 1),*P stutzeri*(*n*=1), and*S aureus*(*n*= 1).↵b Other bacteria from patients in hospital since birth include the following:

*E cloacae*(*n*= 5),*S marcescens*(*n*= 3),*Klebsiella*spp. (*n*= 2),*Bacillus*spp. (*n*=2), coagulase-negative staphylococci (*n*= 2),*S gallolyticus*(*n*= 2),*S anginosus*(*n*= 1), viridians group*Streptococcus*(*n*= 1),*Enterococcus*spp. (*n*= 1), and*C sakazakii*(*n*= 1).↵c Resistance to AMP includes the following: based on in vitro testing for

*E coli*(*n*= 19),*Klebsiella*spp. (*n*= 4), and*H influenza*(*n*= 2); resistance assumed for*E cloacae*(*n*= 6),*S marcescens*(*n*= 3),*C sakazakii*(*n*= 2), and*P stutzeri*(*n*= 1),*S aureus*(*n*= 1), and coagulase-negative staphylococci (*n*= 2).↵d Resistance to both AMP and GEN (community isolates) was based on in vitro testing for

*E coli*(*n*= 1) and resistance assumed for*S aureus*(*n*= 1).↵e Resistance to both AMP and GEN (hospital isolates) was based on in vitro testing for

*E coli*(*n*= 3) and GEN resistant*S marcescens*(*n*= 1); resistance was assumed for coagulase-negative staphylococci (*n*= 2). Of note, all*E cloacae*and*C sakazakii*isolates were GEN susceptible or not tested.↵f Resistance to CEF (third) (community isolates) includes the following: resistance assumed for

*L monocytogenes*(*n*= 3),*E cloacae*(*n*= 1),*C sakazakii*(*n*= 1), and*P stutzeri*(*n*= 1).↵g Resistance to CEF (third) (hospital isolates) includes the following: based on in vitro resistance testing for

*E coli*(*n*= 1); resistance assumed for*E cloacae*(*n*= 5),*S marcescens*(*n*= 3),*C sakazakii*(*n*= 1),*Enterococcus*spp. (*n*= 1), and coagulase-negative staphylococci (*n*= 2).↵h Among survivors (

*n*= 105).